CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 59 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,988,370 | -30.0% | 594,978 | +2.0% | 0.00% | -25.0% |
| Q2 2023 | $18,542,408 | +37.3% | 583,278 | +5.4% | 0.00% | +33.3% |
| Q1 2023 | $13,500,865 | -20.4% | 553,541 | +3.0% | 0.00% | -25.0% |
| Q4 2022 | $16,954,516 | +17.8% | 537,556 | +5.6% | 0.00% | +33.3% |
| Q3 2022 | $14,392,000 | +8.5% | 509,276 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $13,269,000 | -7.7% | 501,877 | +22.2% | 0.00% | 0.0% |
| Q1 2022 | $14,375,000 | +3.9% | 410,618 | -3.8% | 0.00% | +50.0% |
| Q4 2021 | $13,838,000 | +13.2% | 426,838 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $12,224,000 | +25.6% | 414,369 | +9.1% | 0.00% | 0.0% |
| Q2 2021 | $9,729,000 | +917.7% | 379,781 | +445.7% | 0.00% | – |
| Q1 2021 | $956,000 | -12.4% | 69,601 | +5.8% | 0.00% | – |
| Q4 2020 | $1,091,000 | – | 65,805 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |